Kallonen Janica, Glaser Natalie, Bredin Fredrik, Corbascio Matthias, Sartipy Ulrik
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiothoracic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Pulm Circ. 2020 Apr 14;10(2):2045894020918520. doi: 10.1177/2045894020918520. eCollection 2020 Apr-Jun.
Pulmonary endarterectomy is the guideline recommended treatment for chronic thromboembolic pulmonary hypertension, in addition to life-long anticoagulation therapy. The aim was to analyze long-term relative survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. We included all patients who underwent pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension at Karolinska University Hospital between 1997 and 2018 (n = 100). We obtained baseline characteristics and vital status from patient charts and national health-data registers. The expected survival from the general Swedish population matched by age, sex, and year of surgery was obtained from the Human Mortality Database. The relative survival was used as an estimate of cause-specific mortality. The mean age of the patients was 62 years and 39% were women. Most patients were severely symptomatic (95% in New York Heart Association functional class III-IV), and mean preoperative systolic/diastolic (mean) pulmonary artery pressure was 78/27 (45) mmHg. The mean and maximum follow-up time was 7.2 and 22.1 years, respectively. Early (30-day) mortality was 7%. The 15-year observed, expected, and relative survival was 55% (95% confidence interval, 40%-68%), 71%, and 77% (95% confidence interval, 56%-95%), respectively. The 15-year relative survival conditional on 30-day survival was 83% (95% confidence interval, 60%-100%). Although the life expectancy following pulmonary endarterectomy was shorter compared to the general population, the difference was small in those who survived the operation and the early postoperative period. Patients with chronic thromboembolic pulmonary hypertension who are surgical candidates should undergo pulmonary endarterectomy to improve prognosis.
除终身抗凝治疗外,肺动脉内膜剥脱术是慢性血栓栓塞性肺动脉高压的指南推荐治疗方法。目的是分析慢性血栓栓塞性肺动脉高压患者接受肺动脉内膜剥脱术后的长期相对生存率。我们纳入了1997年至2018年间在卡罗林斯卡大学医院接受慢性血栓栓塞性肺动脉高压肺动脉内膜剥脱术的所有患者(n = 100)。我们从患者病历和国家健康数据登记处获取了基线特征和生命状态。通过年龄、性别和手术年份匹配的瑞典普通人群的预期生存率来自人类死亡率数据库。相对生存率用作特定病因死亡率的估计值。患者的平均年龄为62岁,39%为女性。大多数患者症状严重(纽约心脏协会功能分级III-IV级的患者占95%),术前平均收缩压/舒张压(平均)肺动脉压为78/27(45)mmHg。平均和最长随访时间分别为7.2年和22.1年。早期(30天)死亡率为7%。15年的观察生存率、预期生存率和相对生存率分别为55%(95%置信区间,40%-68%)、71%和77%(95%置信区间,56%-95%)。以30天生存率为条件的15年相对生存率为83%(95%置信区间,60%-100%)。尽管肺动脉内膜剥脱术后的预期寿命比普通人群短,但在手术存活且度过术后早期的患者中,差异很小。符合手术条件的慢性血栓栓塞性肺动脉高压患者应接受肺动脉内膜剥脱术以改善预后。